Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy

Future Medicinal Chemistry

Volumn 7, Issue 13, 2015, Pages 1793-1808

  Singh, Natalia N ^a   Lee, Brian M ^a   DiDonato, Christine J ^b,c   Singh, Ravindra N ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2;

ANTISENSE THERAPY; CANONICAL ANALYSIS; DRUG TARGETING; GENETICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SPINAL MUSCULAR ATROPHY; ANIMAL; CHEMISTRY; EXON; MOLECULAR MODEL; MUSCULAR ATROPHY, SPINAL; MUTATION;

ANIMALS; EXONS; HUMANS; MODELS, MOLECULAR; MUSCULAR ATROPHY, SPINAL; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; SURVIVAL OF MOTOR NEURON 1 PROTEIN; SURVIVAL OF MOTOR NEURON 2 PROTEIN;

EID: 84944408452     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.101     Document Type: Review

References (110)

1. Prior TW. Spinal muscular atrophy diagnostics. J. Child Neurol. 22(8), 952-956 (2007
2. Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch. Neurol. 68(8), 979-984 (2011
3. Tiziano FD, Melki J, Simard LR. Solving the puzzle of spinal muscular atrophy: what are the missing pieces?. Am. J. Med. Genet. A 161A(11), 2836-2845 (2013
4. Nurputra DK, Lai PS, Harahap NIF et al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann. Hum. Genet. 77(5), 435-463 (2013
5. Lefebvre S, Bürglen L, Reboullet S et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1), 155-165 (1995
6. McAndrew PE, Parsons DW, Simard LR et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet. 60(6), 1411-1422 (1997
7. Howell MD, Singh NN and Singh RN (2014). Advances in therapeutic development for spinal muscular atrophy. Fut. Med. Chem. 9, 1081-1099 (2014
8. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96(11), 6307-6311 (1999
9. Lorson CL, Strasswimmer J, Yao JM et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 19(1), 63-66 (1998
10. Le TT, Pham LT, Butchbach ME et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14(6), 845-857 (2005
11. Burnett BG, Muñoz E, Tandon A, Kwon DY, Sumner CJ, Fischbeck KH. Regulation of SMN protein stability. Mol. Cell. Biol. 29(5), 1107-1115 (2009
12. Cho S, Dreyfuss G. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev. 24(5), 438-442 (2010
13. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70(2), 358-368 (2002
14. Parsons DW, McAndrew PE, Iannaccone ST, Mendell JR, Burghes AH, Prior TW. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am. J. Hum. Genet. 63(6), 1712-1723 (1998
15. Wirth B, Brichta L, Schrank B et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet. 119(4), 422-428 (2006
16. Tiziano FD, Bertini E, Messina S et al. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul. Disord. 17(5), 400-403 (2007
17. Schrank B, Götz R, Gunnersen JM et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA 94(18), 9920-9925 (1997
18. Hammond SM, Gogliotti RG, Rao V, Beauvais A, Kothary R, DiDonato CJ. Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS ONE 5(12), e15887 (2010
19. Park GH, Kariya S, Monani UR. Spinal muscular atrophy: new and emerging insights from model mice. Curr. Neurol. Neurosci. Rep. 10(2), 108-117 (2010
20. Sleigh JN, Gillingwater TH, Talbot K. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis. Model Mech. 4(4), 457-467 (2011
21. Bebee TW, Dominguez CE, Chandler DS. Mouse models of SMA: tools for disease characterization and therapeutic development. Hum. Genet. 131(8), 1277-1293 (2012
22. Kariya S, Park GH, Maeno-Hikichi Y et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17(16), 2552-2569 (2008
23. Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17(7), 949-962 (2008
24. Kong L, Wang X, Choe DW et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci. 29(3), 842-851 (2009
25. Ling KK, Lin MY, Zingg B, Feng Z, Ko CP. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS ONE 5(11), e15457 (2010
26. Ruiz R, Casanas JJ, Torres-Benito L, Cano R, Tabares L. Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. J. Neurosci. 30(3), 849-57 (2010
27. Lee YI, Mikesh M, Smith I, Rimer M, Thompson W. Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev. Biol. 356(2), 432-444 (2011
28. Mentis GZ, Blivis D, Liu W et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 69(3), 453-467 (2011
29. Dachs E, Hereu M, Piedrafita L, Casanovas A, Calder J, Esquerda JE. Defective neuromuscular junction organization and postnatal myogenesis in mice with severe spinal muscular atrophy. J. Neuropathol. Exp. Neurol. 70(6), 444-461 (2011
30. Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ, Didonato CJ. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J. Neuro. 32(11), 3818-29 (2012
31. Bevan AK, Hutchinson KR, Foust KD et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19(20), 3895-3905 (2010
32. Heier CR, Satta R, Lutz C, DiDonato CJ. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum. Mol. Genet. 19(20), 3906-3918 (2010
33. Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19(20), 4059-4071 (2010
34. Schreml J, Riessland M, Paterno M et al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur. J. Hum. Genet. 21(6), 643-652 (2013
35. Bowerman M, Swoboda KJ, Michalski J-P et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann. Neurol. 72(2), 256-268 (2012
36. Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?. J. Anat. 224(1), 15-28 (2014
37. Kernochan LE, Russo ML, Woodling NS et al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14(9), 1171-1182
38. Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A. p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Hum. Mol. Genet. 18(21), 4035-4045 (2009
39. Farooq F, Molina FA, Hadwen J et al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J. Clin. Invest. 121(8), 3042-3050 (2011
40. Kwon DY, Motley WW, Fischbeck KH, Burnett BG. Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Hum. Mol. Genet. 20(18), 3667-77 (2011
41. Singh NN, Seo J, Ottesen EW, Shishimorova M, Bhattacharya D, Singh RN. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol. Cell. Biol. 31(5), 935-954 (2011
42. Xiao J, Marugan JJ, Zheng W et al. Discovery, synthesis, and biological evaluation of novel SMN protein modulators. J. Med. Chem. 54(18), 6215-6233 (2011
43. Hsu YY, Jong YJ, Tsai HH, Tseng YT, An LM, Lo YC. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice. Br. J. Pharmacol. 166(3), 1114-26 (2012
44. Zhou J, Tawk M, Tiziano FD et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am. J. Hum. Genet. 91(1), 5-14 (2015
45. Oprea GE, Kröber S, McWhorter ML et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320(5875), 524-527 (2008
46. Bebee TW, Dominguez CE, Samadzadeh-Tarighat S, Akehurst KL, Chandler DS. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model. Hum. Mol. Genet. 21(19), 4301-4313 (2012
47. Singh NN, Seo J, Rahn S and Singh RN. A multi-exonskipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes. PLoS ONE 7(11), e49595 (2012
48. Naryshkin NA, Weetall M, Dakka A et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345(6197), 688-693 (2014
49. Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J. Cell Biol. 199(1), 21-25 (2012
50. Porensky PN, Burghes AH. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum. Gene. Ther. 24(5), 489-498 (2013
51. Arnold WD, Burghes AH. Spinal muscular atrophy: development and implementation of potential treatments. Ann. Neurol. 74(3), 348-62 (2013
52. Seo J, Howell MD, Singh NN and Singh RN (2013). Spinal muscular atrophy: An update on therapeutic progress. Biochim. Biophys. Acta. 1832(12), 2180-2190 (2013
53. Singh P, Liew WK, Darras BT. Current advances in drug development in spinal muscular atrophy. Curr. Opin. Pediatr. 25(6), 682-688 (2013
54. Awano T, Kim J-K, Monani UR. Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics 11(4), 786-795 (2014
55. d'Ydewalle C, Sumner CJ. Spinal muscular atrophy therapeutics: where do we stand?. Neurotherapeutics 12(2), 303-316 (2015
56. Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing. J. Biol. Chem. 276(48), 45476-45483 (2001
57. Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K. Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J. Biol. Chem. 277(26), 23271-77 (2002
58. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26(4), 1333-1346 (2006
59. Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol. 6(3), 341-350 (2009
60. Singh NN, Lawler MN, Ottesen EW, Upreti D, Kaczynski JR, Singh RN. An intronic structure enabled by a longdistance interaction serves as a novel target for splicing correction in spinal muscular atrophy. Nucl. Acids Res. 41(17), 8144-8165 (2013
61. Pao PW, Wee KB, Yee WC, Pramono ZA. Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene. Mol. Ther. 22(4), 854-61 (2014
62. Sivanesan S, Howell MD, DiDonato CJ, Singh RN. Antisense oligonucleotide mediated therapy of spinal muscular atrophy. Transl. Neurosc. 4(1), 1-7 (2013
63. ClinicalTrials Database: NCT02193074. https: //clinicaltrials.gov/ct2/show/NCT02193074
64. Muntoni F, Wood MJ. Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug. Discov. 10(8), 621-637 (2011
65. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug. Discov. 11(2), 125-140 (2012
66. Havens MA, Duelli DM, Hastings ML. Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev. RNA 4(3), 247-266 (2013
67. Singh NN and Singh RN. Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model. RNA Biol. 8(4), 600-606 (2011
68. Kashima T, Rao N, Manley JL. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc. Natl Acad. Sci. USA 104(9), 3426-3231 (2007
69. Singh NN, Singh RN, Androphy EJ. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res. 35(2), 371-389 (2007
70. Singh NN, Androphy EJ, Singh RN. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA 10(8), 1291-1305 (2004
71. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol. 10(2), 120-5 (2003
72. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl Acad. Sci. USA 100(7), 4114-4119 (2003
73. Singh NN, Androphy EJ, Singh RN. An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem. Biophys. Res. Commun. 315(2): 381-388 (2004
74. Singh NN, Androphy EJ, Singh RN. The regulation and regulatory activities of alternative splicing of the SMN gene. Crit. Rev. Eukaryot. Gene Expr. 14(4), 271-285 (2004
75. Mende Y, Jakubik M, Riessland M et al. Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing. Hum. Mol. Genet. 19(11), 2154-2167 (2010
76. Xiong HY, Alipanahi B, Lee LJ et al. The human splicing code reveals new insights into the genetic determinants of disease. Science 347(6218), 1254806 (2015
77. Burge CB, Tuschl T, Sharp PA. Splicing of precursors to mRNAs by the spliceosomes. In: The RNA World (2nd Ed). Gesteland RF et al. (Eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 525-560 (1999
78. Buratti E, Baralle F. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol. Cell. Biol. 24(24), 10505-10514 (2004
79. Martinez-Contreras R, Fisette JF, Nasim FU, Madden R, Cordeau M, Chabot B. Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol. 4(2), e21 (2006
80. Shepard PJ, Hertel KJ. Conserved RNA secondary structures promote alternative splicing. RNA 14(8), 1463-1469 (2008
81. Warf MB, Berglund JA. Role of RNA structure in regulating pre-mRNA splicing. Trends Biochem. Sci. 35(3), 169-178 (2010
82. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5(4), e73 (2007
83. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82(4), 834-848 (2008
84. Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro®): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin. Pharmacokinet. 54(2), 133-146 (2015
85. Hua Y, Sahashi K, Rigo F et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478(7367), 123-126 (2011
86. Porensky PN, Mitrpant C, McGovern VL et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 21(7), 1625-1638 (2012
87. Zhou H, Janghra N, Mitrpant C et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum. Gene Ther. 24(3), 331-342 (2013
88. Mitrpant C, Porensky P, Zhou H et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLOS ONE 8(4), e62114 (2013
89. Nizzardo M, Simone C, Salani S et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy ?7 mouse model phenotype. Clin. Ther. 36(3), 340-56. e5 (2014
90. Singh NN, Hollinger K, Bhattacharya D, Singh RN. An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in premRNA splicing. RNA 16(6), 1167-81 (2010
91. Singh NN, Seo J, Ottesen EW, Shishimorova M, Bhattacharya D, Singh RN. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol. Cell. Biol. 31(5), 935-954 (2011
92. Singh NN, Lee BM, Singh RN. Splicing regulation in spinal muscular atrophy by an RNA structure formed by longdistance interactions. Ann. NY Acad. Sci. 1341, 176-187 (2015
93. Cheng CY, Chou F-C, Das R. Modeling complex RNA tertiary folds with Rosetta. Methods Enzymol. 553, 35-64 (2015
94. Keil JM, Seo J, Howell MD, Hsu WH, Singh RN, DiDonato CJ. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol. Ther. Nucl. Acids. 3, e174 (2014
95. Osman EY, Miller MR, Robbins KL et al. Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum. Mol. Genet. 23(18), 4832-4845 (2014
96. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 146(3), 353-358 (2011
97. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol. Ther. 12(6), 1013-1022 (2005
98. Geib T, Hertel KJ. Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS ONE 4(12), e8204 (2009
99. Owen N, Zhou H, Malygin AA et al. Design principles for bifunctional targeted oligonucleotide enhancers of splicing. Nucl. Acids Res. 39(16), 7194-7208 (2011
100. Smith LD, Dickinson RL, Lucas CM et al. A targeted oligonucleotide enhancer of SMN2 exon 7 splicing forms competing quadruplex and protein complexes in functional conditions. Cell Rep. 9(1), 193-205 (2014
101. Marquis J, Meyer K, Angehrn L, Kämpfer SS, Rothen-Rutishauser B, Schümperli D. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol. Ther. 15(8), 1479-86 (2007
102. Meyer K, Marquis J, Trüb J et al. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. Genet. 18(3), 546-555 (2009
103. Voigt T, Meyer K, Baum O, Schümperli D. Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for spinal muscular atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing. Neuromuscul. Disord. 20(11), 744-52 (2010
104. Baughan T, Shababi M, Coady TH, Dickson AM, Tullis GE, Lorson CL. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther. 14(1), 54-62 (2006
105. Dickson A, Osman E, Lorson CL. A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum. Gene Ther. 19(11), 1307-1315 (2008
106. Baughan TD, Dickson A, Osman EY, Lorson CL. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet. 18(9), 1600-1611 (2009
107. Osman EY, Yen PF, Lorson CL. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol. Ther. 20(1), 119-126 (2012
108. Landis SC, Amara SG, Asadullah K et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490(7419), 187-191 (2012
109. Haibe-Kains B, El-Hachem N, Birkbak NJ et al. Inconsistency in large pharmacogenomic studies. Nature 504(7480), 389-393 (2013
110. Perrin S. Preclinical research: make mouse studies work. Nature 507(7493), 423-425 (2014